Neurobiological Technologies Inc (NTII)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

2000 POWELL STREET, SUITE 800 EMERYVILLE, CA 94608

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Companys stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

View SEC Filings from NTII instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% 1 (0.06%) 1 (0.06%) 0.0%
13F shares: 2.545 Million 2.545 Million 0.0% 2.545 Million 2.545 Million 0.0%
% Ownership 9.4178 9.4178
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NTII (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NTII BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FIREFLY VALUE PARTNERS, LP

FIREFLY MANAGEMENT CO GP, LLC

FVP GP, LLC

FVP MASTER FUND LP

FVP US-Q LP

WARSZAWSKI ARIEL

HESLOP RYAN

  • 10% Owner
4,613,222 2010-06-07 0

STUPPIN JOHN B

  • Director
183,876 2009-12-29 0

COHEN ABRAHAM E

  • Director
133,707 2009-11-06 0

KASPER F VAN

  • Director
58,600 2009-10-27 0

SOFAER ABRAHAM D

  • Director
125,931 2009-10-27 0

ELIOT THEODORE

  • Director
17,617 2009-10-27 0

FLETCHER WILLIAM A ACTING CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
83,600 2009-10-27 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

LAMPERT MARK N

BVF INC/IL

  • 10% Owner
  • DIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNER
No longer subject to file 2009-10-21 0

FREIMAN PAUL E

  • FORMER OFFICER AND DIRECTOR
No longer subject to file 2008-12-10 0

J P MORGAN CHASE & CO

  • 10% Owner
No longer subject to file 2008-11-14 0

MAK CAPITAL ONE LLC

MAK CAPITAL FUND LP

KAUFMAN MICHAEL A

SUSSMAN S DONALD

  • 10% Owner
5,220,057 2008-11-14 0

WASIEWSKI WARREN W VICE PRESIDENT, CMO

  • Officer
10,000 2008-11-12 0

LOAR MATTHEW M VP AND CHIEF FINANCIAL OFFICER

  • Officer
25,000 2008-10-22 0

DONDERO JAMES D

HIGHLAND CAPITAL MANAGEMENT LP

STRAND ADVISORS, INC.

  • 10% Owner
4,737,479 2008-10-10 0

LEVY DAVID E VP OF CLINICAL DEVELOPMENT

  • Officer
0 2008-05-30 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
4,938,393 2007-11-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments